Community-based Tuberculosis Tracing and Preventive Therapy (CONTACT)

February 14, 2023 updated by: Maryline Bonnet, Elizabeth Glaser Pediatric AIDS Foundation

Community Intervention for Tuberculosis Active Contact Tracing and Preventive Therapy - a Cluster Randomized Study (CONTACT)

The many gaps observed in the cascade of care of tuberculosis (TB) child contacts occur mostly in the screening, preventive therapy (PT) initiation and PT completion steps and the main drivers of these gaps are considered to be the health system infrastructure, limited worker resources and parents' reluctance to bring their children to the facility for screening. There would be great advantages of using a symptom-based screening at community level where only the symptomatic contacts are referred to hospital for further evaluation and asymptomatic contacts are started on PT in the community. Household or community-based screening is likely to improve the uptake and acceptability of child contact screening and management as well as adherence to PT and to reduce cost and workload at facility level.

This study proposes to compare the cascade of care between two models for TB screening and management of household TB child contacts in two high TB burden and limited resource countries, Cameroon and Uganda. In the facility-based model, children will be screened at facility (Cameroon) or household level (Uganda) and preventive therapy initiation, refills of PT therapy and follow-up will be done at facility level. In the intervention group (community-based model), child contacts will be screened in the household by a community health worker (CHW). Those with symptoms suggestive of TB will be referred to the facility for TB investigations. Asymptomatic child contacts from high risk groups (under-5 years or HIV infected 5-14) will be initiated on PT (3 months isoniazid-rifampicin) in the household. Refills of PT therapy will also be done in the communities by the CHW. In both models, symptomatic children requiring further investigations for TB diagnosis will be referred to a health facility.

Study Overview

Status

Completed

Conditions

Detailed Description

The primary study objective is to compare the proportion of household child TB contacts eligible for PT (under-5 years and HIV-infected children 5-14 years without active TB) who initiate and complete PT using facility-based and decentralized community-based models of care for contact screening and management.

Secondary objectives are:

  1. To compare the facility and community-based models in terms of:

    • The full cascade of care for the initiation and completion of PT in child TB contacts < 5 years or HIV+ children 5-14 years .
    • Cascade of care for the detection and treatment of TB in child contacts (all ages):
    • PT tolerability and adherence among eligible child contacts initiated on PT.
    • Treatment uptake and outcomes for child contacts diagnosed with TB .
    • Child contact outcomes at 6 months after enrollment for all child contacts.
    • Acceptability by the parents/guardians, health personnel and community of the different models of care.
    • Cost and cost-effectiveness of the different models.
    • Fidelity of the implementation of the model activities as compared to the protocol.
  2. To assess the number of adult contact cases diagnosed with TB through the community-based screening.
  3. To compare between the pre- (baseline assessment) and post-intervention (by model of care) data related to:

    • Children diagnosed with TB and registered at facility level and their treatment outcome.
    • Adults diagnosed with TB and registered at facility level and their treatment outcome.
    • PT initiation and outcomes.

This study will be implemented under the frame of the Catalyzing Pediatric TB Innovation (CaP TB) Project, funded by Unitaid and implemented by the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF). The goal of CaP TB is to improve the pediatric TB morbidity and mortality by catalyzing the wide uptake of the new first-line fixed dose combination drugs for children and optimizing the use of these drugs through improved case detection and innovative models of care. In both models of care, contacts with TB suggestive symptoms will be investigated for TB at the cluster facility that is supported by EGPAF within the CaP TB project. In Cameroon the CaP TB project will be implemented in the Central and Littoral regions and in Uganda in the South-West region.

Study Type

Interventional

Enrollment (Actual)

1400

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bonabéri, Cameroon
        • Hôpital de district Bonassama
      • Douala, Cameroon
        • Hôpital de district Log-Baba
      • Edéa, Cameroon
        • Centre Médical d'arrondissement Delangue
      • Mbalmayo, Cameroon
        • Hôpital de district Mbalmayo
      • Mfou, Cameroon
        • Hôpital de district Mfou
      • Nkongsamba, Cameroon
        • Hôpital régional Nkongsamba
      • Okola, Cameroon
        • Hôpital de district Okola
      • Olembe, Cameroon
        • Hôpital de district Olembe
      • Penja, Cameroon
        • Hôpital de district St Jean de Malte
      • Yoko, Cameroon
        • Hôpital de district Yoko
      • Ibanda, Uganda
        • Ishongororo HC IV
      • Ibanda, Uganda
        • Ruhoko HC IV
      • Kabwohe, Uganda
        • Kabwohe Clinical Research Center HC II
      • Kabwohe, Uganda
        • Kabwohe HC IV
      • Kitagata, Uganda
        • Kitagata Hospital
      • Mbarara, Uganda
        • Bubaare HC III
      • Mbarara, Uganda
        • Bwizibwera HC IV
      • Mbarara, Uganda
        • Kakoba HC III
      • Mbarara, Uganda
        • Mbarara Municipal Council HC IV
      • Ntungamo, Uganda
        • Bwongyera HC III
      • Ntungamo, Uganda
        • Itojo Hospital
      • Ntungamo, Uganda
        • Kitwe HC IV
      • Ntungamo, Uganda
        • Ntungamo Ngoma HC III
      • Ntungamo, Uganda
        • Rubaare HC IV
      • Ntungamo, Uganda
        • Rwashamaire HC IV

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Inclusion of the index cases

    • Age > 15 years
    • Newly bacteriologically confirmed TB case (less than a month since diagnosis)
    • Reports child contact(s)
    • Written informed consent signed by the index case and by parents/guardians for minors or incapacitated people
  • Inclusion of contacts

    • Household contact
    • Age
    • Facility-based model in Cameroon: < 5 years or HIV infected 5-14 years and all self-referred adults or children*.
    • Facility-based model in Uganda and community-based model on both countries: all ages
    • Written informed consent signed by adult contacts and by parents/guardians for minors or incapacitated people
    • Written assent for children > 7 years in Cameroon and ≥8 years in Uganda

Under the facility-based model in Cameroon, although there is no systematic request to screen adults or HIV-negative child contacts 5-14 years old, first inclusions showed that some of them came by themselves for TB screening. This justifies their inclusion in the study in order to ensure the completeness of data for all contacts screened under the facility-based model.

Exclusion Criteria:

- Exclusion of index cases

  • Index cases who do not have child household contacts living in the catchment area of one of the study clusters
  • Index cases diagnosed with rifampicin resistance, multidrug-resistant (MDR) or extensively drug-resistant (XDR) TB *Index cases from a household screened within the CONTACT study and that does not declare child contacts from another household.*
  • Index cases that are prisoners

TB confirmed adult contacts cases living in the same household as an index case already enrolled in the study will not be included as new index cases unless they declare additional contacts from another household

- Exclusion of the contacts

  • If the contact is already on PT or on TB treatment

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Facility-based model
Standard of care of each country
Experimental: Community-based model
Screening and initiating preventive therapy in communities
Symptom-based screening of tuberculosis household child contacts by community health workers; initiation of preventive therapy (3 months of a fixed-dose combination of rifampicin-isoniazid or 6 months isoniazid for HIV+ children on protease inhibitors) in the household by a nurse; follow-up of children under preventive therapy by a community health worker for eligible children at community level, and referral of presumptive tuberculosis cases (children and adults) to the facility.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Completion of preventive therapy
Time Frame: 6 months
Proportion of child TB contacts <5 years of age and HIV-infected children of 5-14 years of age who initiate and complete the PT of all child contacts <5 years of age and HIV-infected children of 5-14 years of age declared by the index case
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of children eligible for PT
Time Frame: 6 months
Number of children eligible for PT among screened children
6 months
Proportion of children started on PT
Time Frame: 6 months
Number of children started on PT among those eligible for PT
6 months
Proportion of children who did not complete PT
Time Frame: 6 months
Number of children who did not complete PT among those started on PT
6 months
Proportion of children investigated for TB
Time Frame: 1 month
Number of children with presumptive TB investigated for TB
1 month
Proportion of children diagnosed with TB
Time Frame: 1 month
Number of children diagnosed with TB among those with symptoms suggestive of TB
1 month
Proportion of children started on TB treatment
Time Frame: 1 month
Number of children with TB diagnosis who are started on TB treatment
1 month
Proportion of adult contacts screened
Time Frame: 1 month
Number of adult contacts screened among household identified adult contacts
1 month
Proportion of adults presumptive TB cases
Time Frame: 1 month
Number of adults with symptoms suggestive of TB among those screened for TB
1 month
Proportion of adults diagnosed with TB
Time Frame: 1 month
Number of adults presumptive TB cases diagnosed with TB
1 month
Proportion of children with serious adverse events
Time Frame: 6 months
Number of children with serious adverse events among children started on PT
6 months
Proportion of children with adverse event of interest
Time Frame: 6 months
Number of children with adverse event of interest (peripheral neuropathy, clinical hepatotoxicity) among children on PT
6 months
Treatment adherence
Time Frame: 6 months
Ratio of PT dose taken by the child over the total number of doses prescribed
6 months
Treatment outcomes of children started on TB treatment
Time Frame: 6 months
  • Cured
  • Treatment completed
  • Failure
  • Death
  • Lost to follow up
  • Transferred out
6 months
Proportion of children diagnosed with TB
Time Frame: 6 months
Number of children diagnosed with TB after initiation of PT or children not initiated on PT and not diagnosed with TB at baseline
6 months
TB case detection during pre-intervention period
Time Frame: 2 years
Number of patients registered in the facility TB register one year before intervention
2 years
Proportion of children among all registered TB cases during pre-intervention period
Time Frame: 2 years
Number of children among all patients diagnosed with TB and registered in the facility TB register one year before intervention
2 years
TB treatment outcome of registered TB patients during pre-intervention period
Time Frame: 2 years
  • Cured
  • Treatment completed
  • Failure
  • Death
  • Lost to follow up
  • Transferred out
2 years
Number of children started on PT during pre-intervention period
Time Frame: 2 years
Number of children started on PT from the facility PT register one year before intervention
2 years
Completion rate of children started on PT intervention during pre-intervention period
Time Frame: 2 years
Number of children who completed PT among those started on PT from the facility PT register one year before
2 years
Number of household visits by CHW
Time Frame: 2 years
Number of visits by the CHW to the household for contact screening per household
2 years
Proportion of parents/guardians who accept household visit
Time Frame: 2 years
Acceptability of household visit for contact screening
2 years
Reasons of refusal of household visit
Time Frame: 2 years
Description of screening failures
2 years
Preference for household visit versus facility visit
Time Frame: 2 years
This outcome measures whether the parent/guardian prefers bringing child to the facility rather than having someone coming to his household
2 years
Critical events experienced by CHW during household visit
Time Frame: 2 years
Description of critical events during house visit and how these where dealt with
2 years
Transport cost for household visit by CHW
Time Frame: 2 years
Cost of transportation for the CHW to go from the health facility to a household
2 years
Transport cost for parents/guardian for facility-based screening
Time Frame: 2 years
Cost supported by families to bring child contact to the facility for screening
2 years
Time spent to perform household contact screening visit
Time Frame: 2 years
It includes the time to reach the household, the time spent in the household and the time to go back to the facility for CHW
2 years
Proportion of delivered activities compared to the intended activities of the model
Time Frame: 2 years
This outcome will assess fidelity to study procedures
2 years
Proportion of children screened
Time Frame: 6 months
Number of children screened among child contacts <5 years or HIV-infected 5-14 years declared by the index case
6 months
Proportion of children with presumptive TB
Time Frame: 1 month
Number of children with symptoms suggestive of TB among screened children (< 15 years)
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 14, 2019

Primary Completion (Actual)

August 1, 2022

Study Completion (Actual)

August 1, 2022

Study Registration Dates

First Submitted

January 24, 2019

First Submitted That Met QC Criteria

February 4, 2019

First Posted (Actual)

February 6, 2019

Study Record Updates

Last Update Posted (Actual)

February 16, 2023

Last Update Submitted That Met QC Criteria

February 14, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tuberculosis

Clinical Trials on Screening and initiating preventive therapy in communities

Subscribe